6533b7dafe1ef96bd126f4b7

RESEARCH PRODUCT

Effects of gemfibrozil in hyperlipidemic patients with or without diabetes

subject

description

Abstract Four hundred sixty-one hyperlipidemic men and women, aged 23 to 73 years, with (n = 200) or without (n = 261) non-insulin-dependent diabetes mellitus were included in a study designed to evaluate the efficacy and tolerability of 1,200 mg of gemfibrozil given once daily for 24 weeks. All lipid values improved significantly in both diabetic and nondiabetic patients during treatment. The number of patients with the atherogenic predictor ratio of low-density:high-density lipoprotein cholesterol (HDL-C:LDL-C) >5 decreased by 95% in both patient groups. The number of patients in the highest-risk subgroup with the combination risk factors of LDL-C:HDL-C >5 and triglyceride levels >200 mg/dl was reduced by 77%. Mean body weight and blood pressure decreased significantly in both patient groups. The blood pressure decrease was greater in hypertensive than in normotensive patients. Mean fasting blood glucose levels decreased significantly in the diabetic patients. It is concluded that a single daily dose of gemfibrozil is safe and effective in the treatment of nondiabetic and diabetic patients.